ArticlePlastic and reconstructive surgery. Global open2026
Efficacy and Safety of a Novel Sodium Hyaluronate Composite Solution via Mesotherapy for Facial Rejuvenation: A Multicenter Randomized Controlled Study.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Facial skin aging drives demand for minimally invasive rejuvenation. The technique of injecting skin boosters into the dermis through mesotherapy is increasingly used to improve signs of skin aging. This study evaluates the efficacy and safety of a novel sodium hyaluronate-based composite solution (containing sodium hyaluronate, glycine, proline, leucine, and lysine) for facial rejuvenation. Methods: Participants aged 18 to 65 years with facial skin concerns (dryness, dullness, enlarged pores, reduced elasticity, or fine wrinkles) were randomized in a 2:1 ratio into a treatment group or a control group. The treatment group received 3 monthly intradermal injections, whereas the control group received no intervention. The primary endpoint was the efficacy rate 1 month after the final treatment using the Global Aesthetic Improvement Scale. Secondary endpoints included efficacy rates at different time points and changes in skin hydration and elasticity. Safety was monitored throughout. Results: Of 456 enrolled participants, 439 completed the study (287 treatment, 152 control; 92.94% women). One month posttreatment, the treatment group showed a 97.56% efficacy rate, significantly higher than the control group's 3.95% ( Conclusions: The skin booster (a novel sodium hyaluronate composite solution) delivered via mesotherapy is effective for improving signs of skin aging. With a favorable safety profile, it offers a validated therapeutic option for facial rejuvenation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.